WO2017115252A1 - An oral osmotic pharmaceutical composition of vildagliptin - Google Patents

An oral osmotic pharmaceutical composition of vildagliptin Download PDF

Info

Publication number
WO2017115252A1
WO2017115252A1 PCT/IB2016/057975 IB2016057975W WO2017115252A1 WO 2017115252 A1 WO2017115252 A1 WO 2017115252A1 IB 2016057975 W IB2016057975 W IB 2016057975W WO 2017115252 A1 WO2017115252 A1 WO 2017115252A1
Authority
WO
WIPO (PCT)
Prior art keywords
vildagliptin
salt
hours
composition
released
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/057975
Other languages
French (fr)
Inventor
Mandar Madhukar KODGULE
Amit Bansal
Ganesh SANGLE
Kapileshwar SWAIN
Nitin Saigal
Sanjay Gaikwad
Sunil Kumar AGARWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to BR112018013195A priority Critical patent/BR112018013195A2/en
Priority to MX2018007681A priority patent/MX2018007681A/en
Priority to KR1020187016451A priority patent/KR20180092981A/en
Priority to RU2018120202A priority patent/RU2706706C1/en
Publication of WO2017115252A1 publication Critical patent/WO2017115252A1/en
Priority to PH12018550075A priority patent/PH12018550075A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the invention relates to a novel osmotic pharmaceutical composition comprising vildagliptin or salt thereof.
  • the invention further provides a process of preparing such compositions.
  • Diabetes mellitus is a common disorder more prevalent in developed countries. It is characterized by its clinical manifestations, namely the non-insulin-dependent or maturity onset form, also known as type 2 diabetes and the insulin-dependent or juvenile onset form, also known as type 1 diabetes. It is a metabolic disease in which there is a high blood sugar level over a prolonged period. This disorder is associated with high morbidity and mortality.
  • Dipeptidyl-peptidase-IV (DPP-IV) inhibitors are an oral drug class that was introduced in 2006 and that seems easy to use and do not require regular glucose monitoring or dose adjustments.
  • DPP-IV inhibitors act by inhibiting DPP-IV enzyme, a multifunctional transmembrane glycoprotein enzyme that cleaves N-terminal dipeptides from polypeptides with L-proline or L- alanine at the penultimate position.
  • Vildagliptin is an orally active inhibitor of the DPP-IV enzyme.
  • insulinotropic hormone glucagon- like peptide- 1 GLP-1
  • Some of the GLP-1 is inactivated by the DPP-IV present in plasma and intestinal capillary endothelium. Therefore, if the DPP-IV inhibited, more GLP-1 will be available to activate insulin release from the pancreas.
  • U.S. Patent No. 6,166,063 discloses a DPP-IV inhibitor compound vildagliptin, its use in treating type-2 diabetes mellitus and its pharmaceutical composition.
  • U.S. Patent No. 6,303,661 discloses methods of using an oral inhibitor of DPP-IV or DPP IV-like enzyme activity to reduce blood glucose levels after food intake.
  • U.S. Patent No. 8,143,217 discloses methods of using vildagliptin in combination with insulin to treat hypoglycemic events in a patient with diabetes.
  • European Patent Application, EP 1,537,880 Al relates to a sustained release formulation of DPP-IV inhibitor (Vildagliptin) comprising a hydrophilic polymer.
  • EP 2,191,824 Bl discloses sustained release formulation of DPP-IV inhibitor (Vildagliptin) comprising hydroxypropyl methylcellulose.
  • DPP-IV inhibitor Vildagliptin
  • European Patent Application, EP 2,578,208 Al discloses solid dosage formulation obtained with briquette pressing or compression between rollers and characterized in that it comprises DPP-IV inhibitor.
  • PCT Publication No. WO 2014/029841 Al discloses extended release compositions of an amino-C2-C6-alkyl nitrate and fixed dose combinations with vildagliptin.
  • the existing vildagliptin product is a direct compression tablet with a 25% drug load.
  • Patient adherence to a drug regimen indirectly correlates with frequency of dosing i.e. greater adherence is seen with a once daily dosing regimen compared to a twice daily dosing regimen.
  • the majority of data currently available for vildagliptin is derived from studies based on the immediate release formulation (GALVUS ) having twice daily dosing regimen. There is a need to provide a once a daily formulation of vildagliptin which will provide ease, convenience and reduced side effects profile.
  • a general aspect of the invention discloses an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type
  • the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C and/or about 85%
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5;
  • a seal coat surrounding the core comprising a sustained release coat cellulose acetate surrounding the seal coat;
  • an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vilda
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising about 70% to about 95% by weight cellulose acetate, and
  • step (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • Figure 1A and Figure IB shows in- vitro dissolution profile of vildagliptin composition 1A and composition IB respectively, at acid stage and buffer stage.
  • Figure 2 A shows % DPP-IV inhibition after administration of invention composition 1A and GALVUS ® .
  • Figure 2B shows Plasma-drug concentration profile after administration of invention composition 1A and GALVUS ® .
  • Figure 3 A shows % DPP-IV inhibition after administration of invention composition IB and GALVUS ® .
  • Figure 3B shows Plasma-drug concentration profile after administration of invention composition IB and GALVUS ® .
  • Figure 4 shows in- vitro dissolution profile of comparative vildagliptin composition 6A and 6B at acid stage and buffer stage.
  • a general aspect of the invention discloses an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • osmotic pharmaceutical composition refers to an advanced controlled release solid drug delivery system with a sustained release coat and one or more small laser drilled bores in it.
  • core refers to a matrix or a bilayer or a trilayer or a multilayer component having a drug, osmotic agent and one or more pharmaceutically acceptable excipients.
  • sustained release coat refers to a semi-permeable membrane controlling drug release.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type
  • the composition exhibits an in-vitro release profile such that about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 18% to about 22% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 20% of vildagliptin or salt thereof is released at 2 hours when measured in 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 80% to about 90% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 85% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 25% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 25% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 90% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 90% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 10 ng/ml to about 200 ng/ml, or about 20 ng/ml to about 150 ng/ml, or about 30 ng/ml to about 100 ng/ml, or about 40 ng/ml to about 50 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 10 ng/ml to about 20 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. Alternatively, the composition can decrease DPP-IV enzyme activity in blood plasma by about 70% to about 80% over the period of 24 hours. Alternatively, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 20 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 18 hours.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 16 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 14 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 12 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 10 hours.
  • the core comprises a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof.
  • the drug layer comprises about 45 mg to about 90 mg, or about 55 mg to about 85 mg, or about 65 mg to about 75 mg of vildagliptin or salt thereof.
  • the drug layer comprises about 40 mg, or about 45 mg, or about 50 mg, or about 55 mg, or about 60 mg, or about 65 mg, or about 70 mg, or about 75 mg, or about 80 mg, or about 85 mg, or about 90 mg of vildagliptin or salt thereof.
  • the drug layer comprises about 75 mg of vildagliptin or salt thereof.
  • the drug layer further comprises pharmaceutically acceptable excipients such as swelling polymer like polyethylene oxide having molecular weight of about 100,000 to 200,000, osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the preferred osmotic agent is mannitol and lubricants like magnesium stearate, zinc stearate, sodium stearyl fumarate.
  • the drug layer comprises polyethylene oxide having molecular weight of about 100,000 to 200,000 is present in about 170 mg to about 200 mg, or about 188 mg or about 190 mg or about 195 mg.
  • the drug layer comprises osmotic agent that is mannitol present in about 30 mg to about 50 mg or about 36 mg.
  • the core comprises the push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000.
  • the push layer comprises polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 and is present in about 70 mg to about 100 mg, or about 80 mg to about 90 mg.
  • the push layer comprises polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 and is present in about 85 mg, or 90 mg or 95 mg.
  • the push layer further comprises pharmaceutically acceptable excipients such osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the preferred osmotic agent is sodium chloride, binder such as hydroxypropyl methylcellulose (HPMC) having viscosity of 3cP to 6cP when present in 2% solution, and lubricants like magnesium stearate, zinc stearate, sodium stearyl fumarate.
  • HPMC hydroxypropyl methylcellulose
  • the push layer comprises osmotic agent that is sodium chloride present in about 30 mg to about 50 mg or about 45 mg.
  • the osmotic agent present in drug layer is different than push layer.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core ranges from about 1 :1 to about 1 :10. In another embodiment, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core ranges from about 1 :1 to about 1 :3. Alternatively, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core is about 1 :1.10, or about 1 :1.15, or about 1 :1.20, or about 1 :1.25.
  • the core is surrounded by a seal coat selected from commercially available coating system such as Opadry®.
  • the seal coat is surrounded by a sustained release coat comprising about 80% to about 90% by weight cellulose acetate.
  • the seal coat is surrounded by a sustained release coat comprising about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • the sustained release coat is surrounded by an immediate release drug layer comprising about 20 mg to about 30 mg of vildagliptin or salt thereof, or about 25 mg of vildagliptin or salt thereof.
  • the total amount of vildagliptin or salt thereof present in composition is about 100 mg or about 150 mg or about 200 mg or about 250 mg or about 300 mg, wherein about 90%, or about 80%, or about 70% or about 60% or about 50% of vildagliptin or salt thereof is present in the core of composition and about 10%, or about 20%, or about 30%, or about 40%, or about 50% of vildagliptin or salt thereof is present in the immediate release drug layer.
  • compositions are present in the form of an oral formulation such as a tablet, capsule (including a microcapsule), granule, or powder; of these forms, an oral formulation such as a tablet is preferred.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • a core comprising: (i) a drug
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 95 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 85 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C. In one embodiment of this aspect, about 15%
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C. In one embodiment of this aspect, about 15%
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the core comprises about 75 mg of vildagliptin or salt thereof.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the sustained release coat comprises about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5;
  • a seal coat surrounding the core comprising a sustained release coat cellulose acetate surrounding the seal coat;
  • an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the core comprises about 75 mg of vildagliptin or salt thereof.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the sustained release coat comprises about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising about 70% to about 95% by weight cellulose acetate, and
  • step (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the core comprises about 75 mg of vildagliptin or salt thereof.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the sustained release coat comprises about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising cellulose acetate, and (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°C, and where
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising cellulose acetate
  • step (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • EXAMPLE 1 Osmotic compositions of vildagliptin Total Tab. wt. 504.19 504.19
  • Step II Separately passed mannitol thorough #40 sieve and geometrically blended with Step I mixture.
  • Step II powder blend was granulated with IPA in a rapid mixer granulator by spraying
  • Iron Oxide passed thorough #60 mesh mixed with the step I mixture for 5 minutes.
  • Step II powder blend was granulated with IPA in a rapid mixer granulator by spraying
  • SPM Semi-Permeable membrane
  • step II Seal coated tablets were coated with step I solution until a weight gain of 10% w/w is attained.
  • Opadry solution was added to the drug solution under stirring and mixed for 30 minutes.
  • the drug layer side of the above tablet was drilled by with a 0.6 mm needle using a tablet laser drilling machine.
  • Opadry 03K19229 (clear) was dispersed in IPA and stirred for 30 minutes. MDC was added to the above solution and mixed for 10 minutes.
  • EXAMPLE 2 Dissolution testing of osmotic pharmaceutical compositions of Example 1.
  • Diluent Use dissolution medium as diluent.
  • Diluent Use dissolution medium as diluent.
  • example 1 (1A and IB) compositions 100 mg
  • GALVUS® 50 mg
  • Percent inhibition of DPP-IV was calculated as 100 x (1 - A t /A 0 ), where A 0 was the enzyme activity measured predose and At was the activity measured post-dose at time t in the same treatment period. Plasma drug concentrations were measured using LC-MS method. The results obtained are presented in the form of mean ⁇ SEM in Fig 2A and Fig 2B for example 1A and Fig 3 A and Fig 3B for example IB composition.
  • GALVUS® showed >80% DPP-IV inhibition from 0.5 - 6 hour during first dose and 10.5-16 hour during second dose. Overall, GALVUS maintained >80 % DPP-IV inhibition for 6 hour after each dose. After 6 hour of administration, GALVUS showed DPP-IV inhibition below 80% which correlates with plasma drug concentration.
  • Example 1A composition reported >80% DPP-IV inhibition up to 14 hours which is in alignment with plasma drug concentrations. The drop in DPP-IV inhibition after 20 hours may be attributed to incomplete drug release. Example 1A composition showed consistent and longer DPP-IV inhibition compared with GALVUS®.
  • example IB composition showed > 80% DPP-IV inhibition up to 8 hour and more than 70% up to 14 hour.
  • DPP-IV activity correlated with plasma drug concentrations and in-vitro results. Relative Bioavailability of 95% achieved against GALVUS .
  • the similar and consistent PK/PD outcomes can be anticipated in human volunteers in view of drug half-life and clearance correlations between humans and dogs.
  • composition Example IB Tablets of composition Example IB were packed in Alu Alu blisters and were loaded on stability under the 40°C ⁇ 2°C & 75%RH ⁇ 5%RH and 30°C ⁇ 2°C & 65%RH ⁇ 5%RH and evaluated for assay, dissolution and impurity profile.
  • the invention composition (example IB) remain storage stable at 40°C ⁇ 2°C & 75%RH ⁇ 5%RH and 30°C ⁇ 2°C & 65%RH ⁇ 5%RH conditions.
  • the compositions were also proved to dissolution stable at these conditions.
  • EXAMPLE 5 Osmotic compositions of vildagliptin
  • Example 5 The compositions of Example 5 were prepared by the process as described in Example 1.
  • EXAMPLE 6 Comparative examples
  • the comparative example compositions of Example 6 were prepared by the process described in Example 1.
  • the comparative example compositions 6A and 6B were subjected to in- vitro dissolution testing at the condition provided in example 2 and compared with invention composition 1A.
  • Figure 4 shows in- vitro dissolution profile of comparative vildagliptin composition 6A and 6B at acid stage and buffer stage and following table points out the difference between invention composition and comparative examples:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1:1 to about 1:5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat. Also provided is process of preparing such compositions.

Description

AN ORAL OSMOTIC PHARMACEUTICAL COMPOSITION OF VILDAGLIPTIN
TECHNICAL FIELD OF THE INVENTION
The invention relates to a novel osmotic pharmaceutical composition comprising vildagliptin or salt thereof. The invention further provides a process of preparing such compositions.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a common disorder more prevalent in developed countries. It is characterized by its clinical manifestations, namely the non-insulin-dependent or maturity onset form, also known as type 2 diabetes and the insulin-dependent or juvenile onset form, also known as type 1 diabetes. It is a metabolic disease in which there is a high blood sugar level over a prolonged period. This disorder is associated with high morbidity and mortality. Dipeptidyl-peptidase-IV (DPP-IV) inhibitors are an oral drug class that was introduced in 2006 and that seems easy to use and do not require regular glucose monitoring or dose adjustments. DPP-IV inhibitors act by inhibiting DPP-IV enzyme, a multifunctional transmembrane glycoprotein enzyme that cleaves N-terminal dipeptides from polypeptides with L-proline or L- alanine at the penultimate position. Vildagliptin is an orally active inhibitor of the DPP-IV enzyme. After a meal intake, insulinotropic hormone glucagon- like peptide- 1 (GLP-1) is released which in turn induces insulin release from the pancreas. Some of the GLP-1 is inactivated by the DPP-IV present in plasma and intestinal capillary endothelium. Therefore, if the DPP-IV inhibited, more GLP-1 will be available to activate insulin release from the pancreas. The advantage of this mechanism of insulin release is that insulin is secreted only in response to a meal. Therefore, problems of hypoglycemia associated with other diabetes drugs are less likely with a DPP-IV inhibitor. Vildagliptin alone or in combination with other anti-diabetic agents is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus in multiple clinical conditions. Vildagliptin is marketed by Novartis in the Europe in the form of tablets under the trademark GALVUS . The recommended daily dose of Vildagliptin is lOOmg, administered as one dose of 50mg in the morning and one dose of 50mg in the evening.
U.S. Patent No. 6,166,063 discloses a DPP-IV inhibitor compound vildagliptin, its use in treating type-2 diabetes mellitus and its pharmaceutical composition. U.S. Patent No. 6,303,661 discloses methods of using an oral inhibitor of DPP-IV or DPP IV-like enzyme activity to reduce blood glucose levels after food intake. U.S. Patent No. 8,143,217 discloses methods of using vildagliptin in combination with insulin to treat hypoglycemic events in a patient with diabetes. European Patent Application, EP 1,537,880 Al relates to a sustained release formulation of DPP-IV inhibitor (Vildagliptin) comprising a hydrophilic polymer. European Patent No. EP 2,191,824 Bl discloses sustained release formulation of DPP-IV inhibitor (Vildagliptin) comprising hydroxypropyl methylcellulose. European Patent Application, EP 2,578,208 Al discloses solid dosage formulation obtained with briquette pressing or compression between rollers and characterized in that it comprises DPP-IV inhibitor. PCT Publication No. WO 2014/029841 Al discloses extended release compositions of an amino-C2-C6-alkyl nitrate and fixed dose combinations with vildagliptin.
The existing vildagliptin product is a direct compression tablet with a 25% drug load. Patient adherence to a drug regimen indirectly correlates with frequency of dosing i.e. greater adherence is seen with a once daily dosing regimen compared to a twice daily dosing regimen. The majority of data currently available for vildagliptin is derived from studies based on the immediate release formulation (GALVUS ) having twice daily dosing regimen. There is a need to provide a once a daily formulation of vildagliptin which will provide ease, convenience and reduced side effects profile.
SUMMARY OF THE INVENTION
A general aspect of the invention discloses an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat. In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ± 0.5°C. In another embodiment, the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ± 0.5°C. In another embodiment, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ± 0.5°C. In another embodiment, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C and/or about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another aspect of the invention, there is provided a kit comprising an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
In another aspect of the invention, there is provided a kit comprising an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In another aspect of the invention, there is provided a method of treating type 2 diabetes, said method comprises administering to a patient in a need thereof an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
In another aspect of the invention, there is provided a method of treating type 2 diabetes, said method comprises administering to a patient in a need thereof an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In another aspect of the invention, there is provided a process of preparing an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C, and wherein said process comprises steps of: (a) preparing the drug layer in the form of a granules comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients,
(b) preparing a push layer in the form of a granules comprising polyethylene oxide,
(c) compressing the granules of the drug layer and the push layer to form the core,
(d) seal coating the core of step (c),
(e) coating the seal coat of step (d) with the sustained release coat comprising about 70% to about 95% by weight cellulose acetate, and
(f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1A and Figure IB shows in- vitro dissolution profile of vildagliptin composition 1A and composition IB respectively, at acid stage and buffer stage.
Figure 2 A shows % DPP-IV inhibition after administration of invention composition 1A and GALVUS®.
Figure 2B shows Plasma-drug concentration profile after administration of invention composition 1A and GALVUS®.
Figure 3 A shows % DPP-IV inhibition after administration of invention composition IB and GALVUS®.
Figure 3B shows Plasma-drug concentration profile after administration of invention composition IB and GALVUS®.
Figure 4 shows in- vitro dissolution profile of comparative vildagliptin composition 6A and 6B at acid stage and buffer stage.
DETAILED DESCRIPTION OF THE INVENTION
A general aspect of the invention discloses an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat. The term "osmotic pharmaceutical composition" refers to an advanced controlled release solid drug delivery system with a sustained release coat and one or more small laser drilled bores in it. The term "core" refers to a matrix or a bilayer or a trilayer or a multilayer component having a drug, osmotic agent and one or more pharmaceutically acceptable excipients.
The term "sustained release coat" refers to a semi-permeable membrane controlling drug release.
In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat.
In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In one embodiment, the composition exhibits an in-vitro release profile such that about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C. Alternatively, the composition exhibits an in-vitro release profile such that about 18% to about 22% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C. Alternatively, the composition exhibits an in-vitro release profile such that about 20% of vildagliptin or salt thereof is released at 2 hours when measured in 0. IN HC1 at 37°C ± 0.5°C. In another embodiment, the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C. Alternatively, the composition exhibits an in-vitro release profile such that about 80% to about 90% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C. Alternatively, the composition exhibits an in-vitro release profile such that about 85% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. Alternatively, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 25% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In another embodiment, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. Alternatively, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 25% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C.
In another embodiment, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. Alternatively, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 90% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. Alternatively, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 90% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 10 ng/ml to about 200 ng/ml, or about 20 ng/ml to about 150 ng/ml, or about 30 ng/ml to about 100 ng/ml, or about 40 ng/ml to about 50 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. Alternatively, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 10 ng/ml to about 20 ng/ml at 24 hours after once daily oral administration.
In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. Alternatively, the composition can decrease DPP-IV enzyme activity in blood plasma by about 70% to about 80% over the period of 24 hours. Alternatively, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 20 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 18 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 16 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 14 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 12 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 10 hours.
In another embodiment, the core comprises a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof. In another embodiment, the drug layer comprises about 45 mg to about 90 mg, or about 55 mg to about 85 mg, or about 65 mg to about 75 mg of vildagliptin or salt thereof. Alternatively, the drug layer comprises about 40 mg, or about 45 mg, or about 50 mg, or about 55 mg, or about 60 mg, or about 65 mg, or about 70 mg, or about 75 mg, or about 80 mg, or about 85 mg, or about 90 mg of vildagliptin or salt thereof. Alternatively, in another embodiment the drug layer comprises about 75 mg of vildagliptin or salt thereof. In further embodiment, the drug layer further comprises pharmaceutically acceptable excipients such as swelling polymer like polyethylene oxide having molecular weight of about 100,000 to 200,000, osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. The preferred osmotic agent is mannitol and lubricants like magnesium stearate, zinc stearate, sodium stearyl fumarate. In another embodiment, the drug layer comprises polyethylene oxide having molecular weight of about 100,000 to 200,000 is present in about 170 mg to about 200 mg, or about 188 mg or about 190 mg or about 195 mg. In another embodiment, the drug layer comprises osmotic agent that is mannitol present in about 30 mg to about 50 mg or about 36 mg. In another embodiment, the core comprises the push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000. In another embodiment, the push layer comprises polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 and is present in about 70 mg to about 100 mg, or about 80 mg to about 90 mg. Alternatively, the push layer comprises polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 and is present in about 85 mg, or 90 mg or 95 mg.
In another embodiment, the push layer further comprises pharmaceutically acceptable excipients such osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. The preferred osmotic agent is sodium chloride, binder such as hydroxypropyl methylcellulose (HPMC) having viscosity of 3cP to 6cP when present in 2% solution, and lubricants like magnesium stearate, zinc stearate, sodium stearyl fumarate. In another embodiment, the push layer comprises osmotic agent that is sodium chloride present in about 30 mg to about 50 mg or about 45 mg. In another embodiment, the osmotic agent present in drug layer is different than push layer. In another embodiment, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
In another embodiment, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core ranges from about 1 :1 to about 1 :10. In another embodiment, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core ranges from about 1 :1 to about 1 :3. Alternatively, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core is about 1 :1.10, or about 1 :1.15, or about 1 :1.20, or about 1 :1.25.
In another embodiment, the core is surrounded by a seal coat selected from commercially available coating system such as Opadry®. In another embodiment, the seal coat is surrounded by a sustained release coat comprising about 80% to about 90% by weight cellulose acetate. In another embodiment, the seal coat is surrounded by a sustained release coat comprising about 90% by weight cellulose acetate. In another embodiment, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2.
In another embodiment, the sustained release coat is surrounded by an immediate release drug layer comprising about 20 mg to about 30 mg of vildagliptin or salt thereof, or about 25 mg of vildagliptin or salt thereof.
In another embodiment, the total amount of vildagliptin or salt thereof present in composition is about 100 mg or about 150 mg or about 200 mg or about 250 mg or about 300 mg, wherein about 90%, or about 80%, or about 70% or about 60% or about 50% of vildagliptin or salt thereof is present in the core of composition and about 10%, or about 20%, or about 30%, or about 40%, or about 50% of vildagliptin or salt thereof is present in the immediate release drug layer.
In another embodiment, the invention compositions are present in the form of an oral formulation such as a tablet, capsule (including a microcapsule), granule, or powder; of these forms, an oral formulation such as a tablet is preferred.
In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment, the osmotic agent present in drug layer is different than push layer. In another embodiment of this aspect, the sustained release coat comprises about 40 mg cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2.
In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 95 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment of this aspect, the osmotic agent present in drug layer is different than push layer. In another embodiment of this aspect, the sustained release coat comprises about 40 mg cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2.
In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 85 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment of this aspect, the osmotic agent present in drug layer is different than push layer. In another embodiment of this aspect, the sustained release coat comprises about 40 mg cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2. In another aspect of the invention, there is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment of this aspect, the osmotic agent present in drug layer is different than push layer. In another embodiment of this aspect, the sustained release coat comprises about 40 mg cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2. In another aspect of the invention, there is provided a kit comprising an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
In another aspect of the invention, there is provided a kit comprising an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C.
In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
In another embodiment of this aspect, the core comprises about 75 mg of vildagliptin or salt thereof. In another embodiment of this aspect, the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3. In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment of this aspect, the sustained release coat comprises about 90% by weight cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2.
In another aspect of the invention, there is provided a method of treating type 2 diabetes, said method comprises administering to a patient in a need thereof an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat. In another aspect of the invention, there is provided a method of treating type 2 diabetes, said method comprises administering to a patient in a need thereof an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C.
In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
In another embodiment of this aspect, the core comprises about 75 mg of vildagliptin or salt thereof. In another embodiment of this aspect, the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3. In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment of this aspect, the sustained release coat comprises about 90% by weight cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2.
In another aspect of the invention, there is provided a process of preparing an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C, and wherein said process comprises steps of:
(a) preparing the drug layer in the form of a granules comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients, (b) preparing a push layer in the form of a granules comprising polyethylene oxide,
(c) compressing the granules of the drug layer and the push layer to form the core,
(d) seal coating the core of step (c),
(e) coating the seal coat of step (d) with the sustained release coat comprising about 70% to about 95% by weight cellulose acetate, and
(f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
In one embodiment of this aspect, about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C. In another embodiment of this aspect, the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
In another embodiment of this aspect, the core comprises about 75 mg of vildagliptin or salt thereof. In another embodiment of this aspect, the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3. In another embodiment of this aspect, the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight. In another embodiment of this aspect, the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins. In another embodiment of this aspect, the sustained release coat comprises about 90% by weight cellulose acetate. In another embodiment of this aspect, the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm2 or about 0.7 mm2.
In another aspect of the invention, there is provided a process of preparing an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ± 0.5°C, and wherein said process comprises steps of:
(a) preparing the drug layer in the form of a granules comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients,
(b) preparing a push layer in the form of a granules comprising polyethylene oxide,
(c) compressing the granules of the drug layer and the push layer to form the core,
(d) seal coating the core of step (c),
(e) coating the seal coat of step (d) with the sustained release coat comprising cellulose acetate, and (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
In another aspect of the invention, there is provided a process of preparing an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ± 0.5°C, and wherein said process comprises steps of:
(a) preparing the drug layer in the form of a granules comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients,
(b) preparing a push layer in the form of a granules comprising polyethylene oxide,
(c) compressing the granules of the drug layer and the push layer to form the core,
(d) seal coating the core of step (c),
(e) coating the seal coat of step (d) with the sustained release coat comprising cellulose acetate, and
(f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition. While the invention has been described in term of its specific embodiments, certain modification and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention.
EXAMPLES
EXAMPLE 1 : Osmotic compositions of vildagliptin
Figure imgf000026_0001
Total Tab. wt. 504.19 504.19
Drug coating (immediate release)
19 Vildagliptin 25.00 25.00
20 Opadry 03A690050 25.00 25.00
(clear)
21 IPA 94.00 94.00
22 MDC 219.00 219.00
Total Tab. wt. 554.19 554.19
Actual Total Tab. wt. 554.19 554.19
Top Coat
23 Opadry 03K19229(clear) 16.63 16.63
24 Water 220.00 -
25 IPA - q.s.
26 MDC - q.s.
Final Tab. wt. 570.82 570.82
Manufacturing process:
Drug Layer:
I. Vildagliptin and Polyox N 80 were passed thorough #40 sieve.
II. Separately passed mannitol thorough #40 sieve and geometrically blended with Step I mixture.
III. The Step II powder blend was granulated with IPA in a rapid mixer granulator by spraying
IPA on the dry mix to get uniform sized granules.
IV. The above granules were dried in a fluid bed dryer at an inlet temperature of 40+5 °C for appropriate time till an LOD of less than 2 % is attained.
V. The dried granules were passed thorough #40 mesh sieve and further lubricated the
granules with pre- sifted magnesium stearate for 5 minutes.
Push Layer:
I. Polyox WSR 303 and HPMC E-5 were passed thorough #60 mesh sieve.
II. Iron Oxide passed thorough #60 mesh mixed with the step I mixture for 5 minutes.
III. The Step II powder blend was granulated with IPA in a rapid mixer granulator by spraying
IPA on the dry mix to get uniform sized granules.
IV. The above granules were dried in a fluid bed dryer at an inlet temperature of 40+5 °C for appropriate time till an LOD of less than 2 % is attained.
V. The dried granules were passed thorough #40 mesh sieve and further lubricated the
granules with pre- sifted magnesium stearate for 5 minutes. Compression:
I. The above two lubricated granules of drug layer and push layer were compressed into a bilayered tablet using 10.00 mm round shallow concave tooling in a rotary bilayered compression machine.
Seal Coating:
I. Opadry 03K19229 (clear) was dispersed in IPA and stir for 30 minutes. Added MDC to the above solution and mix for 10 minutes.
II. The bilayered tablets were seal coated with the above solution till a weight gain of 3% w/w is attained.
Micro-porous Semi-Permeable membrane (SPM) (Extended release) coating:
I. Cellulose acetate 398-10 in was dispersed in acetone under stirring. PEG 3350 was
dissolved in water and mixed the solution with cellulose acetate solution for 40 minutes.
II. Seal coated tablets were coated with step I solution until a weight gain of 10% w/w is attained.
Drug Layering:
I. Vildagliptin was dissolved in 60% MDC under stirring.
II. Separately Opadry 03A690050 (clear) was dispersed in IPA for 10 minutes and remaining
40% of MDC added in the solution.
III. Opadry solution was added to the drug solution under stirring and mixed for 30 minutes.
IV. Further the SPM coated tablets layered with the above solution of drug and binder till the desired concentration of drug (25 mg) was layered on the tablet as a loading dose.
Drilling
I. The drug layer side of the above tablet was drilled by with a 0.6 mm needle using a tablet laser drilling machine.
Top coat:
I. Opadry 03K19229 (clear) was dispersed in IPA and stirred for 30 minutes. MDC was added to the above solution and mixed for 10 minutes.
II. Top coated the above tablets (drilled on the drug layer side) with the above solution till a weight gain of 2.5-3% w/w was attained.
EXAMPLE 2: Dissolution testing of osmotic pharmaceutical compositions of Example 1.
In-vitro percentage drug release was estimated using the following change over dissolution method.
ACID STAGE:
Dissolution parameters: Medium 0.1N Hydrochloric acid
Volume 900 mL
Apparatus USP Type I (basket)
Rotational speed 100 RPM
Temperature 37°C±0.5°C
Time 1 h, 2 h
Diluent Use dissolution medium as diluent.
After completion of dissolution in acid stage, the acid medium was discarded or decanted carefully and the tablets were dried to preserve for buffer stage.
BUFFER STAGE:
Dissolution parameters:
Medium Phosphate buffer pH 6.8
Volume 900 mL
Apparatus USP Type I (basket)
Rotational speed 100 RPM
Temperature 37°C±0.5°C
Time 1, 2, 4, 8, 12, 16, 18, 22 hours
Diluent Use dissolution medium as diluent.
Composition of example 1A and IB, when subjected to acid stage, about 25% of vildagliptin or salt thereof was released at 2 hours and when subjected buffer stage, about 80% of vildagliptin or salt thereof was released at 24 hours as shown in Fig 1A and Fig IB. EXAMPLE 3: Measurement of DPP-IV inhibition by administration of osmotic pharmaceutical composition of Example 1.
Preclinical studies were carried out on male beagle dogs to evaluate the PK/PD profile of Example
1 (1A and IB) compositions. Plasma drug concentrations and DPP-IV enzyme activity were
®
assessed and compared with GALVUS . Dogs weighing 10.5 to 13.2 kg were received from the Dog House Facility, Wockhardt Research Centre, Aurangabad. Dogs were housed under controlled kennel condition with a 12h light and 12h dark cycle and given access to food once in a day with water ad-libitum. Animals were fasted for 14 hours before the test drug administration, randomized in different treatment arms (n = 4 - 5) with comparable average body weight. Following fasting, animals were treated with single oral dose of example 1 (1A and IB) compositions (100 mg) and two doses of GALVUS® (50 mg) at 0 and 10 hour. Blood samples were collected at 0 (before) and 0.5, 1, 2, 3, 3.25, 3.5, 4, 6, 8, 10, 10.5, 11, 12, 14, 16, 20, 24 and 30 h post-dose. Blood collected was centrifuged, plasma was separated and stored in two aliquots at -80°C for DPP-IV enzyme activity and drug concentration measurement. DPP-IV enzyme activity assay was performed by measuring fluorescence velocities released from fluorogenic substance 7-Amino-4-methylcoumarin (AMC) cleaved from substrate Gly-Pro-AMC by the activity of DPP-IV enzyme at
Figure imgf000030_0001
360 nm and e = 460 nm wavelength. Percent inhibition of DPP-IV was calculated as 100 x (1 - At/A0), where A0 was the enzyme activity measured predose and At was the activity measured post-dose at time t in the same treatment period. Plasma drug concentrations were measured using LC-MS method. The results obtained are presented in the form of mean ± SEM in Fig 2A and Fig 2B for example 1A and Fig 3 A and Fig 3B for example IB composition.
As shown in Fig 2 A and Fig 2B, GALVUS® showed >80% DPP-IV inhibition from 0.5 - 6 hour during first dose and 10.5-16 hour during second dose. Overall, GALVUS maintained >80 % DPP-IV inhibition for 6 hour after each dose. After 6 hour of administration, GALVUS showed DPP-IV inhibition below 80% which correlates with plasma drug concentration. Example 1A composition reported >80% DPP-IV inhibition up to 14 hours which is in alignment with plasma drug concentrations. The drop in DPP-IV inhibition after 20 hours may be attributed to incomplete drug release. Example 1A composition showed consistent and longer DPP-IV inhibition compared with GALVUS®. As shown in Fig 3A and Fig 3B, example IB composition showed > 80% DPP-IV inhibition up to 8 hour and more than 70% up to 14 hour. DPP-IV activity correlated with plasma drug concentrations and in-vitro results. Relative Bioavailability of 95% achieved against GALVUS . The similar and consistent PK/PD outcomes can be anticipated in human volunteers in view of drug half-life and clearance correlations between humans and dogs.
EXAMPLE 4: Stability testing of composition of vildagliptin
Tablets of composition Example IB were packed in Alu Alu blisters and were loaded on stability under the 40°C± 2°C & 75%RH ± 5%RH and 30°C± 2°C & 65%RH ± 5%RH and evaluated for assay, dissolution and impurity profile.
Figure imgf000030_0002
Buffer stage (6.8 pH)
3 h 32 - 34 32 - 33
4 h 35 - 40 35 - 38
6 h 42 39 52 42 42 46
10 h 59 - 74 59 - 60
14h 78 - 90 78 - 72
20 h 87 78 94 87 89 82
24 h 91 92 96 91 93 87
RELATED SUBSTANCES
Highest Unknown 0.04 0.08 0.16 0.04 0.15 0.23 impurities
Total Related substances 0.19 0.24 0.68 0.19 0.59 1.35
As shown in above table, the invention composition (example IB) remain storage stable at 40°C± 2°C & 75%RH ± 5%RH and 30°C± 2°C & 65%RH ± 5%RH conditions. The compositions were also proved to dissolution stable at these conditions.
EXAMPLE 5: Osmotic compositions of vildagliptin
Figure imgf000031_0001
10 Magnesium stearate 1.00 1.00 1.00
11 IPA q.s. q.s. q.s.
Total 145.00 145.00 135.00
Wt of core Tablet 445.00 445.00 435.00
Seal coating (3%)
Opadry
12 13.35 13.35 13.35 03K19229(clear)
13 IPA q.s. q.s. q.s.
14 MDC q.s. q.s. q.s.
Total Tab. wt. 458.35 458.35 448.35
Sustain release coat (10%)
Cellulose acetate 398-
15 41.26 41.26 41.26
10
16 PEG3350 4.58 4.58 4.58
17 Water q.s. q.s. q.s.
18 Acetone q.s. q.s. q.s.
Total Tab. wt. 504.19 504.19 494.19
Drug coating (immediate release)
19 Vildagliptin 25.00 25.00 25.00
Opadry
20 25.00 25.00 25.00 03A690050(clear)
21 IPA 94.00 94.00 94.00
22 MDC 219.00 219.00 219.00
Total Tab. wt. 554.19 554.19 544.19
Actual Total Tab. wt. 554.19 554.19 544.19
Top Coat
Opadry
23 16.63 16.63 16.63
03K19229(clear)
24 Water - - -
25 IPA q.s. q.s. q.s.
26 MDC q.s. q.s. q.s.
Final Tab. wt. 570.82 570.82 560.82
Manufacturing process:
The compositions of Example 5 were prepared by the process as described in Example 1. EXAMPLE 6: Comparative examples
Figure imgf000033_0001
Total Tab. wt. 504.19 1164.19 451.19
Drug coating (immediate release)
19 Vildagliptin 25.00 25.00 25.00
20 Opadry 25.00 25.00 25.00
03A690050(clear)
21 IPA 94.00 94.00 94.00
22 MDC 219.00 219.00 219.00
Total Ta ·>. wt. 554.19 1214.19 501.19
Actual Total Tab. wt. 554.19 1214.19 501.19
Top Coat
23 Opadry 16.63 16.63 16.63
03K19229(clear)
24 Water 220.00 220.00 220.00
25 IPA - - -
26 MDC - - -
Final Ta 3. Wt. 570.82 1230.82 517.82
The comparative example compositions of Example 6 were prepared by the process described in Example 1. The comparative example compositions 6A and 6B were subjected to in- vitro dissolution testing at the condition provided in example 2 and compared with invention composition 1A.
Figure 4 shows in- vitro dissolution profile of comparative vildagliptin composition 6A and 6B at acid stage and buffer stage and following table points out the difference between invention composition and comparative examples:
Figure imgf000034_0001

Claims

CLAIMS We claim:
1. An osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof in the drug layer to polyethylene oxide in the push layer ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; and (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; wherein the pharmaceutical composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C.
2. The pharmaceutical composition of claim 1, wherein about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ± 0.5°C.
3. The pharmaceutical composition of claim 1, wherein the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
4. The pharmaceutical composition of claim 3, wherein about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
5. The pharmaceutical composition of claim 1, wherein the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C.
6. The pharmaceutical composition of claim 1, wherein the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ± 0.5°C.
7. The pharmaceutical composition of claim 1, wherein the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
8. The pharmaceutical composition of claim 1, wherein the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
9. The pharmaceutical composition of claim 1, wherein the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration to a human subject.
10. The pharmaceutical composition of claim 9, wherein the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration to a human subject.
11. The pharmaceutical composition of claim 1, wherein the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours.
12. The pharmaceutical composition of claim 1, wherein the core comprises about 75 mg of vildagliptin or salt thereof.
13. The pharmaceutical composition of claim 1, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1:1 to about 1 :3.
14. An osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; and (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; wherein the pharmaceutical composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ± 0.5°C.
15. The pharmaceutical composition of claim 14, wherein the composition exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ± 0.5°C.
PCT/IB2016/057975 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin Ceased WO2017115252A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR112018013195A BR112018013195A2 (en) 2015-12-28 2016-12-23 vildagliptin oral osmotic pharmaceutical composition
MX2018007681A MX2018007681A (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin.
KR1020187016451A KR20180092981A (en) 2015-12-28 2016-12-23 Oral osmotic pharmaceutical composition of Vildagliptin
RU2018120202A RU2706706C1 (en) 2015-12-28 2016-12-23 Oral vildagliptin osmotic pharmaceutical composition
PH12018550075A PH12018550075A1 (en) 2015-12-28 2018-06-01 An oral osmotic pharmaceutical composition of vildagliptin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4891/MUM/2015 2015-12-28
IN4891MU2015 2015-12-28

Publications (1)

Publication Number Publication Date
WO2017115252A1 true WO2017115252A1 (en) 2017-07-06

Family

ID=57966046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/057975 Ceased WO2017115252A1 (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin

Country Status (6)

Country Link
KR (1) KR20180092981A (en)
BR (1) BR112018013195A2 (en)
MX (1) MX2018007681A (en)
PH (1) PH12018550075A1 (en)
RU (1) RU2706706C1 (en)
WO (1) WO2017115252A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166063A (en) 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6303661B1 (en) 1996-04-25 2001-10-16 Probiodrug Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
EP1537880A1 (en) 2002-09-11 2005-06-08 Takeda Pharmaceutical Company Limited Sustained release preparation
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2191824A1 (en) * 2005-06-10 2010-06-02 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US8143217B2 (en) 2005-09-20 2012-03-27 Novartis Ag Use of DPP-IV inhibitor to reduce hypoglycemic events
EP2578208A1 (en) 2011-10-06 2013-04-10 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303661B1 (en) 1996-04-25 2001-10-16 Probiodrug Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
US6166063A (en) 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1537880A1 (en) 2002-09-11 2005-06-08 Takeda Pharmaceutical Company Limited Sustained release preparation
EP2191824A1 (en) * 2005-06-10 2010-06-02 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
EP2191824B1 (en) 2005-06-10 2012-03-14 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US8143217B2 (en) 2005-09-20 2012-03-27 Novartis Ag Use of DPP-IV inhibitor to reduce hypoglycemic events
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2578208A1 (en) 2011-10-06 2013-04-10 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Also Published As

Publication number Publication date
PH12018550075A1 (en) 2019-01-28
MX2018007681A (en) 2018-11-14
BR112018013195A2 (en) 2018-12-11
RU2706706C1 (en) 2019-11-20
KR20180092981A (en) 2018-08-20

Similar Documents

Publication Publication Date Title
TWI483943B (en) Pharmaceutical composition, pharmaceutical dosage form, preparation method thereof and use thereof
JP4474162B2 (en) Pharmaceutical composition for use in the treatment of type II diabetes
EP2590631B1 (en) Formulation for co-therapy treatment of diabetes
CN101959406A (en) Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
EP2210595A1 (en) Active coating of pharmaceutical dosage forms
US20060141023A1 (en) Pharmaceutical compositions containing abiguanide-glitazone combination
CN101932241A (en) Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor
KR20140007247A (en) Controlled release compositions with reduced food effect
EP4114365A1 (en) Pharmaceutical composition comprising sglt2 inhibitor
JP2013508370A (en) Pharmaceutical composition comprising a combination of a dipeptidyl peptidase-4 inhibitor and pioglitazone
WO2016016770A1 (en) A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof
WO2021076066A1 (en) Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
WO2014170770A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
HU231052B1 (en) Stable pharmaceutical composition containing bisoprolol and ramipril
WO2023012817A1 (en) A pharmaceutical composition comprising combination of dapagliflozin and sitagliptin
CN103251594B (en) Repaglinide/metformin combo tablet
WO2016016772A1 (en) A novel modified release pharmaceutical composition of dpp-iv inhibitors or pharmaceutically acceptable salt thereof
WO2014167437A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
WO2017115252A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
WO2023007511A1 (en) A pharmaceutical composition comprising combination of sglt2 inhibitor and dpp-iv inhibitor
KR100774774B1 (en) Metformin sustained release preparation and preparation method thereof
WO2026053141A1 (en) Composition comprising dapagliflozin and sitagliptin, and method of preparation thereof
KR102362342B1 (en) Composite tablet comprising vildagliptin and metformin
KR20240176609A (en) Composite tablet comprising linagliptin and metformin
WO2026003869A1 (en) Modified release oral tablets for management of diabetes and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16834195

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12018550075

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20187016451

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/007681

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018013195

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2018120202

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112018013195

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180626

122 Ep: pct application non-entry in european phase

Ref document number: 16834195

Country of ref document: EP

Kind code of ref document: A1